Shi-Ying HeShenzhen Salubris Pharmaceuticals Co. Ltd关注立即认领分享关注立即认领分享基本信息浏览量:0职业迁徙个人简介暂无内容研究兴趣论文共 2 篇作者统计合作学者相似作者按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选时间引用量主题期刊级别合作者合作机构Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind studyJin Zhang,Wei Zhang,Jie Yan,Qian Ge,Xiao-Hong Lu,Shao-Xing Chen,Wen-Jie Xu,Ying Li,Jin-Feng Li,Shi-Ying He,Ji-Guang WangHypertension Researchno. 8 (2023): 2024-2032引用1浏览0WOSNATURE引用10A randomized, double-blind, placebo-controlled, single, and multiple dose-escalation Phase I clinical trial to investigate the safety, pharmacokinetic, and pharmacodynamic profiles of oral S086, a novel angiotensin receptor-neprilysin inhibitor, in healthy Chinese volunteersYue Hu,Hong Zhang,Xiaojiao Li,Jiajia Mai,Lizhi Yang,Jie Yan,Ying Li,Jingchao Sun,Wenjie Xu,Shiying He,Jinfeng Li,Min WuEXPERT OPINION ON INVESTIGATIONAL DRUGS(2022)引用2浏览0WOS引用20作者统计合作学者合作机构D-Core合作者学生导师暂无相似学者,你可以通过学者研究领域进行搜索筛选数据免责声明页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn